{"id":61313,"date":"2026-03-25T22:07:41","date_gmt":"2026-03-25T14:07:41","guid":{"rendered":"https:\/\/flcube.com\/?p=61313"},"modified":"2026-03-25T22:07:42","modified_gmt":"2026-03-25T14:07:42","slug":"shyndec-pharmaceutical-licenses-eisai-myonal-generic-from-scienpharm-rmb-10-5-million-deal-targets-muscle-relaxant-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61313","title":{"rendered":"Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm \u2013 RMB 10.5 Million Deal Targets Muscle Relaxant Market"},"content":{"rendered":"\n

Shanghai Shyndec Pharmaceutical Co., Ltd.<\/strong> (SHA: 600420<\/a>) announced a licensing agreement<\/strong> with Shanghai ScienPharm<\/strong>, obtaining rights to the latter’s generic version of Eisai’s Myonal (eperisone)<\/strong> for RMB 10.5 million (USD 1.5 million)<\/strong>. The centrally acting muscle relaxant<\/strong>, used for cervicobrachial syndrome, periarthritis of the shoulder, low back pain, and spastic paralysis<\/strong>, is currently under marketing review in China<\/strong>, positioning Shyndec to capture share in the RMB 2+ billion muscle relaxant market<\/strong> upon approval.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensee<\/strong><\/td>Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)<\/td><\/tr>
Licensor<\/strong><\/td>Shanghai ScienPharm<\/td><\/tr>
Asset<\/strong><\/td>Generic eperisone (Myonal copycat)<\/td><\/tr>
Originator<\/strong><\/td>Eisai (Japan) \u2013 Myonal brand<\/td><\/tr>
Deal Value<\/strong><\/td>RMB 10.5 million (USD 1.5 million)<\/strong><\/td><\/tr>
Product Status<\/strong><\/td>Under marketing review in China (NMPA approval pending)<\/td><\/tr>
Therapeutic Class<\/strong><\/td>Centrally acting muscle relaxant<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Indications<\/h2>\n\n\n\n
Attribute<\/th>Eperisone Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Centrally acting muscle relaxant<\/strong> \u2013 inhibits gamma motor neurons, reduces muscle spindle sensitivity<\/td><\/tr>
Primary Indications<\/strong><\/td>Cervicobrachial syndrome<\/strong> (neck-shoulder-arm pain); periarthritis of shoulder<\/strong>; low back pain<\/strong><\/td><\/tr>
Secondary Indication<\/strong><\/td>Spastic paralysis<\/strong> from underlying neurological diseases<\/td><\/tr>
Market Position<\/strong><\/td>Established brand (Eisai Myonal) with decades of clinical use<\/strong> in Japan and Asia; no generic competition<\/strong> in China currently<\/td><\/tr>
Route<\/strong><\/td>Oral (convenient outpatient therapy)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Context<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Muscle Relaxant Market<\/strong><\/td>RMB 2\u20133 billion annually<\/strong>; aging population and sedentary lifestyle drive chronic musculoskeletal pain prevalence<\/td><\/tr>
Eperisone Differentiation<\/strong><\/td>Dual action<\/strong> \u2013 muscle relaxation + mild analgesic effect; less sedation<\/strong> vs. traditional benzodiazepine muscle relaxants (e.g., diazepam)<\/td><\/tr>
Generic Opportunity<\/strong><\/td>Eisai Myonal imported\/premium priced<\/strong>; domestic generic offers 30\u201350% cost reduction<\/strong> and NRDL listing potential<\/strong><\/td><\/tr>
Shyndec Strategy<\/strong><\/td>Pain management portfolio expansion<\/strong> \u2013 complements existing NSAIDs and neuropathic pain assets; leverages hospital rehabilitation medicine relationships<\/td><\/tr>
ScienPharm Position<\/strong><\/td>Development-to-licensing model<\/strong> \u2013 monetizes ANDA filing without building commercial infrastructure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n